Immunotherapy Plus Capivasertib for Metastatic Bladder Cancer

Immunotherapy Plus Capivasertib for Metastatic Bladder Cancer
Conditions: Advanced Urothelial Carcinoma

Interventions: Drug: capivasertib

Sponsors: VA Office of Research and Development

Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

August 29, 2026Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments